- Centers & Specialties
- Clinical Interests
- Sarcoma and Connective Tissue Oncology
- Gastrointestinal tumor
- Desmoid tumor
- Medical Education
- MD, PhD, New York University
- Residency, Massachusetts General Hospital
- Fellowship, Brigham and Women's Hospital|Fellowship, Dana Farber Cancer Institute
- Board Certifications
- Medical Oncology
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Connecticut
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Research Summary
- Dr. Choy is dedicated to research, teaching, and caring for patients with sarcomas, chordomas, and desmoid tumors. His research endeavors include basic laboratory research, translational studies, and clinical trials all aimed at improving care for cancer patients.
In the laboratory, Choy collaborates with Dr. Zhenfeng Duan and Dr. Francis Hornicek to study the genetics and biology of chemotherapy resistance.In collaboration with investigators at MIT and DFCI, Choy has collected 100 osteosarcoma tumor samples and genotyped them for over one thousand mutations occurring in oncogenes and tumor suppressor genes. He has currently validated 15 mutations and these findings were presented at the international Connective Tissue Oncology Society (CTOS) meeting in November 2009. Choy also holds joint collaborative sessions with investigators at MIT, sponsored by the Koch Institute, to explore further translational projects to benefit sarcoma patients.
Choy has led the growth of an active clinical research program in sarcomas, expanding the number of clinical trials to 12 trials currently, increasing participation in DF/HCC phase I programs, and increasing the overall enrollment rate onto studies. This success in growing our sarcoma program has led to five abstracts that were presented at this year's annual ASCO meeting.Choy's work has been recognized by a career development award from Harvard Catalyst.
Choy, E.*, Yelensky, R.*, Bonakdar, S., et al. (2008) "Genetic Analysis of Human Traits In-Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines." PLOS Genetics, 4(11):e1000287. *equally contributing first-authors
Duan, Z.*, Choy, E.*, Harmon, D., Yang, C., Ryu, K., Schwab, J., Mankin, H., and Hornicek, F. (2009) "Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picrophodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines." Mol. Cancer Ther. 8(8):2122-30. Epub 2009 Jul 28. *equally contributing first-authors
Choy, E., Digumarthy, S., and Koplin, S. (2009) "A 23 year old man with cough, hoarseness, and fever." Case Records of the Massachusetts General Hospital, New Engl J Med. 361(21):2080-7.
Choy, E. and Philips, M.R. (2000) "Expression and activity of a prenylcysteine-directed carboxyl methyltransferase." Methods in Enzymology 325, 101-114.
Dai, Q., Choy, E., Chiu, V., Romano, J., Slivka, S.R., Steitz, S.A., Michaelis, S., and Philips, M.R. (1998) "Mammalian Prenylcysteine Prenyltransferase is in the Endoplasmic Reticulum." Journal of Biological Chemistry 273(24), 15030-15034.
Choy, E., Chiu, V.K., Silletti, J., Feoktistov, M., Morimoto, T., Michaelson, D., Ivanov, I.E., and Philips, M.R. (1999) "Endomembrane Trafficking of Ras: the CAAX Motif Targets Proteins to the ER and Golgi." Cell 98, 69-80.
A young sailor from Maine will compete with his team for a gold medal in the Paralympic sailing events in Rio de Janeiro. Hugh Freund, 28, who lost his lower leg to cancer as a teenager, will race for the U.S. Sailing Team along with two other disabled athletes as part of a team in the Three-Person Keelboat (Sonar) event.
55 Fruit Street
Boston, MA 02114-2696